TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2194417
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics (neomycin and erythromycin)
Study: 2194417
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral and intravenous antibiotics
Study: 369735
Drug: Flunisolide nasal
Normalized name: flunisolide nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunisolide nasal spray (0.025% solution, 200 microgram daily dosage)
Study: 24507118
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU), no intervention
Study: 20801500
Drug: Ivabradine (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine (titrated to a maximum of 7.5 mg twice daily)
Study: 15664719
Drug: Increased 12-step
Normalized name: STEP 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased 12-step participation during the first 3 months of treatment
Study: 15664719
Drug: Individual Drug
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual Drug Counseling based on a 12-step model
Study: 10579471
Drug: 200 mL
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mL double-strength grapefruit juice
Study: 1751081
Drug: Na+ modeling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Na+ modeling (Na+ = 149 meq/L)
Study: 1751081
Drug: Standard Na+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Na+ dialysate (Na+ = 140 meq/L)
Study: 24869973
Drug: PLD (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD (30 mg/m(2)) and trabectedin (1.1 mg/m(2)) in overweight and obese patients (n = 48)
Study: 24869973
Drug: PLD (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD (30 mg/m(2)) and trabectedin (1.1 mg/m(2)) in normal weight patients (n = 26)
Study: 12117660
Drug: Combined SCG
Normalized name: microcrystalline cellulose 102 SCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined SCG (2 mg four times daily) and fluticasone propionate powder 50 microg b.i.d. (group FS)
Study: 10672387
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream applied over skin areas corresponding to injection sites one hour before nerve blocks, placebo intravenous normal-saline injection 2 minutes before the first nerve block.
Study: 10672387
Drug: Intravenous alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alfentanil 10 micrograms.kg‐1, placebo cream applied.
Study: 10672387
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream and intravenous normal-saline at similar time intervals prior to the nerve blocks.
Study: 7485665
Drug: Not using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not using condoms due to starting oral contraceptive pill regimens
Study: 4053698
Drug: Erythromycin 500
Normalized name: erythromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 500 mg twice daily for seven days
Study: 4053698
Drug: Erythromycin 500
Normalized name: erythromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 500 mg twice daily for four days
Study: 29343256
Drug: 3 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/d green cardamom for 10 weeks
Study: 21466944
Drug: Linking and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linking and retaining a person in treatment
Study: 3128309
Drug: Oral Ftorafur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Ftorafur (1 g/m2/day for 21 days)
Study: 3128309
Drug: Intravenous 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 5-fluorouracil (5-FU) (500 mg/m2/day for 5 days)
Study: 28695324
Drug: Almonds (56
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almonds (56 g daily)
Study: 25514559
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg catechins
Study: 25514559
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg theaflavins
Study: 25514559
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg theaflavins
Study: 25514559
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of theaflavins
Study: 31977817
Drug: Romosozumab (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romosozumab (70 mg, 140 mg, 210 mg)
Study: 30802304
Drug: Selective decontamination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective decontamination of the digestive tract (SDD) with oral colistin, tobramycin, and amphotericin B
Study: 30802304
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving intravenous cefazolin and metronidazole for perioperative prophylaxis
Study: 28881549
Drug: Cholera vaccine
Normalized name: Cholera Vaccine
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholera vaccine infused with antacids
Study: 20691481
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR 300 mg/day (for inadequate responders)
Study: 15492131
Drug: hs-CRP >
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-CRP > or = 3.0 mg/L
Study: 11566622
Drug: Local administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local administration of IL-1beta (10 ng/ml, once a day for 7 days)
Study: 8181260
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oral pirenzepine
Study: 29995697
Drug: AnonVT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: AnonVT with the nonvasodilating beta‐blocker metoprolol
Study: 28157412
Drug: Oral jet
Normalized name: Jet Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral jet nebulizer
Study: 22448907
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (physical therapy, manual stretching)
Study: 19507268
Drug: Tianwang Buxin
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tianwang Buxin Pills (TBPs)
Study: 15139870
Drug: Methadone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone maintenance (n = 91) with monthly 1 hour/week of psychosocial therapy during the first 6 months
Study: 15139870
Drug: 180-day detoxification
Normalized name: ARTEMISIA VULGARIS ROOT 4.5 mg in 30 mg / CINNAMON 3 mg in 30 mg / CALENDULA OFFICINALIS FLOWER 4.5 mg in 30 mg / MENTHA PIPERITA LEAF 9 mg in 30 mg TOPICAL LIQUID [HOUKEA Lymphatic Detoxification Anti-Inflammatory Slimming Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180-day detoxification (n = 88) with 3 hours/week of psychosocial therapy and 14 education sessions during the first 6 months
Study: 9648550
Drug: Bromocriptine (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (low-dose D2 dopamine receptor agonist)
Study: 7988261
Drug: Cisplatin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (75 mg/m2 on days 1 and 29) and fluorouracil (1 g/m2 for 24 h as continuous infusion on days 1 to 4 and 29 to 32) with thoracic radiation (30 Gy in 15 fractions on days 1 to 19)
Study: 2567439
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at points specific for the treatment of substance abuse
Study: 30921645
Drug: Irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan hydrochloride liposome injection (IHLI)
Study: 28679449
Drug: Abatacept 3
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept 3 mg/kg on day 1, 15, and 29, followed by 10 mg/kg every 28 days for 5 months
Study: 26596672
Drug: Afatinib alone
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib alone 40 mg orally once per day
Study: 26596672
Drug: Afatinib plus
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib plus vinorelbine 40 mg per day plus intravenous vinorelbine 25 mg/m2 once per week
Study: 23808999
Drug: Berberine hydrochloride
Normalized name: Berberine Hydrochloride
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberine hydrochloride (500 mg) three times daily before meals for 3 months
Study: 29180454
Drug: Sacubitril/valsartan (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan (8 weeks treatment)
Study: 15723448
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg every 12 hours for a total of 5 doses)
Study: 15723448
Drug: Naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500 mg every 12 hours for a total of 5 doses)
Study: 3120345
Drug: Placebo four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo four times daily
Study: 7625622
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms of misoprostol twice daily
Study: 7625622
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms of misoprostol three times daily
Study: 7625622
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms of misoprostol four times daily
Study: 7625622
Drug: Misoprostol twice
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol twice daily vs. Misoprostol three times daily
Study: 7625622
Drug: Misoprostol four
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol four times daily
Study: 7625622
Drug: Misoprostol twice
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol twice daily and three times daily
Study: 343500
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nitrazepam
Study: 21098507
Drug: Phenylbutyrate therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylbutyrate therapy
Study: 19212615
Drug: Transcatheter arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter arterial infusion (TAI) of 120 mg/body cisplatin twice a month at an interval of 4 weeks
Study: 12439700
Drug: Amifostine (740
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (740 mg/m²) before HDM (200 mg/m²)
Study: 25180558
Drug: Additional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional therapy sessions (AT)
Study: 21136031
Drug: Rehabilitation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation therapy for 3 months
Study: 19916293
Drug: Acupuncture (thick-needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (thick-needle subcutaneous penetration of Shendao (GV 11), retained for 4 h/time, once daily, 5 times/week)
Study: 19916293
Drug: Medication (Levocetirizine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Levocetirizine Hydrochloride tablets, 5 mg/time, once daily for first two weeks, then once every other day in the 3rd and 4th weeks, and once every 3 days in the last two weeks)
Study: 15182272
Drug: Salbutamol 100
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol 100 microg/puff, 12 puffs daily
Study: 15182272
Drug: Ipratropium 20
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium 20 microg/puff, 12 puffs daily
Study: 9660095
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg melatonin
Study: 8018001
Drug: Bisoprolol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 2.5 mg/d and Hydrochlorothiazide 6.25 mg/d
Study: 8018001
Drug: Hydrochlorothiazide 6.25
Normalized name: hydrochlorothiazide 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 6.25 mg/d
Study: 789844
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (100 mug three times daily)
Study: 21877102
Drug: Dyskinetic PD
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dyskinetic PD subjects off L-dopa
Study: 21877102
Drug: Non-dyskinetic PD
Normalized name: Poly Hist PD
DrugBank: Thonzylamine (DB11235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-dyskinetic PD subjects off L-dopa
Study: 8550745
Drug: Sodium phosphate
Normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium phosphate infusion
Study: 8550745
Drug: Sham infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham infusion (sodium chloride)
Study: 1646724
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (3.0 g) with 5 mg glipizide
Study: 1646724
Drug: Aluminium hydroxide
Normalized name: Aluminium hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminium hydroxide (1.0 g) with 5 mg glipizide
Study: 1646724
Drug: Control (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (150 ml water with 5 mg glipizide)
Study: 31925414
Drug: Medication adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication adherence reminder and symptom management intervention using the Symptom Management Toolkit during eight automated telephone weekly calls.
Study: 24820145
Drug: Atorvastatin, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin, 20 mg/day for 3 months
Study: 17499292
Drug: Intrarectal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal lidocaine gel instillation before periprostatic neurovascular bundle block
Study: 17499292
Drug: Periprostatic neurovascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periprostatic neurovascular bundle block without lidocaine gel instillation
Study: 15350440
Drug: Enteric-coated mycophenolate
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated mycophenolate sodium (EC-MPS) at a dose of 1.44 g/d (0.450 g/m² bid for children)
Study: 11205489
Drug: EGCG 200
Normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG 200 mg
Study: 26471236
Drug: Polyphenon E
Normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyphenon E 200 mg
Study: 11205489
Drug: EGCG 400
Normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG 400 mg
Study: 15958649
Drug: Polyphenon E
Normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyphenon E 400 mg
Study: 11205489
Drug: EGCG 600
Normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG 600 mg
Study: 26471236
Drug: Polyphenon E
Normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyphenon E 600 mg
Study: 11205489
Drug: EGCG 800
Normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG 800 mg
Study: 15958649
Drug: Polyphenon E
Normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyphenon E 800 mg
Study: 27983689
Drug: Abobotulinum toxin
Normalized name: tetanus toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abobotulinum toxin A (100 units into each of the five lumbar extensor spinae muscles, total dose 500 to 1000 units)
Study: 15854167
Drug: Infliximab treatment
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab treatment (5 mg/kg for induction, plus two maintenance infusions 8 weeks apart)
Study: 10235439
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (4g daily for 12 weeks)
Study: 10235439
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil (4g daily for 12 weeks)
Study: 1858085
Drug: Inhaled 15-(s)-hydroxyeicosatetraenoic
Normalized name: Methylcellulose (15 MPA.S)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled 15-(s)-hydroxyeicosatetraenoic acid (15-HETE) 80 nmol
Study: 30160043
Drug: 6 mg/d
Normalized name: EMSAM 6 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/d melatonin supplements
Study: 20659225
Drug: High FODMAP
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High FODMAP diet (50 g/day)
Study: 17965289
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide synthase inhibitor nitro‐L‐arginine methyl ester (L‐NAME) at doses of 0.5, 1, 2, and 4 mg/kg intravenously over 60 min
Study: 17965289
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide synthase inhibitor nitro‐L‐arginine methyl ester (L‐NAME)
Study: 17965289
Drug: Placebo (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (30 ml normal saline)
Study: 14572573
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg infliximab maintenance therapy
Study: 14572573
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg infliximab maintenance therapy
Study: 14572573
Drug: Single 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 5 mg/kg infliximab infusion (control group)
Study: 8958890
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (starting at 40 mg/day, reducing by 5 mg every other day)
Study: 8958890
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (2 mg daily)
Study: 1586049
Drug: Nasal oxygen
Normalized name: TUBE,NASAL OXYGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal oxygen at 3 L/min delivered by concentrator
Study: 1586049
Drug: Room air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room air at 3 L/min delivered by defective concentrator
Study: 1586049
Drug: N/A (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: N/A (no gas therapy)
Study: 3857938
Drug: Intravaginal pessary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal pessary of 3 mg prostaglandin E2 (PGE2)
Study: 30712148
Drug: E-cigarettes with
Normalized name: E-Z Scrub with Ultradex
Approvals — FDA: no, EMA: no, PMDA: no
Description: E-cigarettes with nicotine salt formulations
Study: 30712148
Drug: myblu 40-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: myblu 40-mg nicotine salt formulation
Study: 27430941
Drug: Listening to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Listening to 432 Hz music during endodontic treatment
Study: 27430941
Drug: No music
Approvals — FDA: no, EMA: no, PMDA: no
Description: No music during endodontic treatment
Study: 22919757
Drug: High-dose Ganciclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Ganciclovir (7.5 mg/kg in inducement phase, 10 mg/kg in maintaining phase)
Study: 22919757
Drug: Low-dose Ganciclovir
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Ganciclovir (5 mg/kg in inducement and maintaining phases)
Study: 22919757
Drug: Low-dose Ganciclovir
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Ganciclovir
Study: 20436079
Drug: Uncoupling index
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncoupling index for cartilage collagen metabolism calculated from PIIANP and CTX-II measurements
Study: 18778469
Drug: Lumiracoxib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiracoxib 400 mg od
Study: 18778469
Drug: Rofecoxib 25
Normalized name: rofecoxib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 25 mg od
Study: 16171525
Drug: Interferon (IFN)-alpha
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon (IFN)-alpha in combination with lamivudine (n = 35)
Study: 16171525
Drug: Interferon (IFN)-alpha
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon (IFN)-alpha alone or in combination with lamivudine
Study: 11841050
Drug: Silymarin MZ-80
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin MZ-80 (150 mg t.i.d. per day)
Study: 229091
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received 4 drug chemotherapy (lomustine, methotrexate, cyclophosphamide, vincristine) and radiotherapy (3000 rad to primary chest lesion).
Study: 23279003
Drug: Ustekinumab 45
Normalized name: USTEKINUMAB 45MG/0.5ML INJ 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 45 mg (Initial Responders)
Study: 23279003
Drug: Ustekinumab 90
Normalized name: ustekinumab 90 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 90 mg (Initial Responders)
Study: 23279003
Drug: Ustekinumab 45
Normalized name: USTEKINUMAB 45MG/0.5ML INJ 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 45 mg (Partial Responders)
Study: 23279003
Drug: Ustekinumab 90
Normalized name: ustekinumab 90 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 90 mg (Partial Responders)
Study: 22298147
Drug: Health-nutrition education
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health-nutrition education and IFA pediatric tablet intervention with parental involvement
Study: 12650785
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.i.d. for 2 weeks
Study: 12650785
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.i.d. plus ranitidine 300 mg HS for 4 weeks
Study: 12650785
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg QAM and QHS for 2 weeks